Syndax Pharmaceuticals Inc (SNDX) — Cash Flow-to-Debt Ratio
Syndax Pharmaceuticals Inc (SNDX) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of $-50.34 Million could theoretically repay 0% of its total liabilities ($431.05 Million) in one year. Explore SNDX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Syndax Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Syndax Pharmaceuticals Inc across 15 annual periods. Also explore SNDX total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Syndax Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Syndax Pharmaceuticals Inc. For market capitalisation and broader financial context, see Syndax Pharmaceuticals Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.69x | $-322.98 Million | $465.08 Million | ▼ -10.3% |
| 2024 | -0.63x | $-274.90 Million | $436.69 Million | ▲ +77.0% |
| 2023 | -2.74x | $-160.60 Million | $58.68 Million | ▲ +39.0% |
| 2022 | -4.49x | $-133.68 Million | $29.79 Million | ▼ -736.1% |
| 2021 | 0.71x | $29.13 Million | $41.29 Million | ▲ +147.9% |
| 2020 | -1.47x | $-71.26 Million | $48.42 Million | ▲ +7.2% |
| 2019 | -1.59x | $-50.61 Million | $31.93 Million | ▲ +28.5% |
| 2018 | -2.22x | $-68.53 Million | $30.89 Million | ▼ -53.9% |
| 2017 | -1.44x | $-47.37 Million | $32.87 Million | ▼ -2.0% |
| 2016 | -1.41x | $-35.16 Million | $24.87 Million | ▼ -1250.8% |
| 2015 | -0.10x | $-2.43 Million | $23.20 Million | ▲ +86.5% |
| 2014 | -0.78x | $-14.39 Million | $18.53 Million | ▲ +44.5% |
| 2013 | -1.40x | $-7.29 Million | $5.21 Million | ▼ -364.3% |
| 2012 | -0.30x | $-9.28 Million | $30.80 Million | ▲ +28.3% |
| 2011 | -0.42x | $-10.02 Million | $23.84 Million | — |